Insuman Comb 30

Insulin human, the active ingredient in Insuman Comb 30, is a short‑acting insulin presented as a 30/70 (U/mL) injection solution for subcutaneous administration. It is used to control blood glucose levels in patients with type 1 and type 2 diabetes mellitus, providing both rapid and intermediate‑acting insulin coverage and helps maintain target glycemic ranges.

GNH USA supplies Insuman Comb 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established cold‑chain logistics and regulatory support for each market.

Insuman Comb 30, a human insulin formulation, is used in the management of diabetes mellitus to regulate blood glucose. - Type 1 diabetes mellitus: provides basal and prandial insulin to achieve glycemic control. - Type 2 diabetes mellitus: supplements endogenous insulin to improve glucose homeostasis. - Insulin‑requiring diabetes (any type): offers a combined rapid‑acting and intermediate‑acting profile for flexible dosing.

Common side effects are typically mild and related to the pharmacologic action of insulin or the injection process.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased caloric storage due to improved glucose utilization. - Lipodystrophy: localized fat accumulation or loss at repeated injection sites. - Mild nausea or abdominal discomfort. - Transient headache.

Serious or Rare Side Effects: - Severe hypoglycemia with loss of consciousness or seizures. - Anaphylactic reaction: rash, swelling, difficulty breathing. - Insulin edema: peripheral swelling due to fluid retention. - Hypokalemia: low potassium levels, potentially causing cardiac arrhythmias. - Acute allergic response to the formulation excipients. - Unexplained persistent hyperglycemia despite dose adjustments.

Before using Insuman Comb 30, consider the following safety measures. - Monitor blood glucose regularly: adjust dose based on readings and clinical response. - Avoid hypoglycemia: ensure carbohydrate intake if symptoms appear. - Use with caution in renal or hepatic impairment: dose may need modification. - Pregnancy and lactation: category B, discuss risks and benefits with a healthcare provider. - Driving or operating machinery: be aware of potential hypoglycemia affecting alertness. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 30 may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycemia symptoms, increasing risk. - MAO inhibitors: may potentiate insulin’s glucose‑lowering effect. - Sulfonylureas or meglitinides: combined use can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring dose adjustment. - Corticosteroids: can reduce insulin effectiveness, necessitating higher doses. - Oral contraceptives: may affect glucose control, warranting closer monitoring.